Biotechnological Applications in Medicine
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347698 Which of the following statements is incorrect about gene therapy in ADA deficiency?

1 Patient does not require periodic infusion of genetically engineered lymphocytes.
2 Lymphocytes are then introduced in the body of patient.
3 A functional ADA cDNA using a retroviral vector is introduced into these lymphocytes.
4 Lymphocytes from patients' blood are taken out and cultured.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347701 In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

1 Gene isolated from marrrow cells producing ADA is introduced into cells at embryonic stages.
2 Lymphocytes from patient's blood are grown in culture, outside the body.
3 Genetically engineered lumphocytes are not immortal cells.
4 Retroviral vector is introduced into these lymphocytes.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347702 In order for gene therapy to be most effective, genes should be inserted in?

1 WBC
2 RBC
3 Stem cells
4 All the above
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347703 For the first time, gene therapy was tried on a 4 year old girl to treat which of the following enzyme deficiency in the year _?

1 Deoxyadenosine Aminase, 1983
2 Adenosine Deaminase, 1990
3 Adenosine Deaminase, 1983
4 Deoxyadenosine Aminase, 1990
NEET Test Series from KOTA - 10 Papers In MS WORD WhatsApp Here
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347698 Which of the following statements is incorrect about gene therapy in ADA deficiency?

1 Patient does not require periodic infusion of genetically engineered lymphocytes.
2 Lymphocytes are then introduced in the body of patient.
3 A functional ADA cDNA using a retroviral vector is introduced into these lymphocytes.
4 Lymphocytes from patients' blood are taken out and cultured.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347701 In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

1 Gene isolated from marrrow cells producing ADA is introduced into cells at embryonic stages.
2 Lymphocytes from patient's blood are grown in culture, outside the body.
3 Genetically engineered lumphocytes are not immortal cells.
4 Retroviral vector is introduced into these lymphocytes.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347702 In order for gene therapy to be most effective, genes should be inserted in?

1 WBC
2 RBC
3 Stem cells
4 All the above
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347703 For the first time, gene therapy was tried on a 4 year old girl to treat which of the following enzyme deficiency in the year _?

1 Deoxyadenosine Aminase, 1983
2 Adenosine Deaminase, 1990
3 Adenosine Deaminase, 1983
4 Deoxyadenosine Aminase, 1990
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347698 Which of the following statements is incorrect about gene therapy in ADA deficiency?

1 Patient does not require periodic infusion of genetically engineered lymphocytes.
2 Lymphocytes are then introduced in the body of patient.
3 A functional ADA cDNA using a retroviral vector is introduced into these lymphocytes.
4 Lymphocytes from patients' blood are taken out and cultured.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347701 In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

1 Gene isolated from marrrow cells producing ADA is introduced into cells at embryonic stages.
2 Lymphocytes from patient's blood are grown in culture, outside the body.
3 Genetically engineered lumphocytes are not immortal cells.
4 Retroviral vector is introduced into these lymphocytes.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347702 In order for gene therapy to be most effective, genes should be inserted in?

1 WBC
2 RBC
3 Stem cells
4 All the above
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347703 For the first time, gene therapy was tried on a 4 year old girl to treat which of the following enzyme deficiency in the year _?

1 Deoxyadenosine Aminase, 1983
2 Adenosine Deaminase, 1990
3 Adenosine Deaminase, 1983
4 Deoxyadenosine Aminase, 1990
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347698 Which of the following statements is incorrect about gene therapy in ADA deficiency?

1 Patient does not require periodic infusion of genetically engineered lymphocytes.
2 Lymphocytes are then introduced in the body of patient.
3 A functional ADA cDNA using a retroviral vector is introduced into these lymphocytes.
4 Lymphocytes from patients' blood are taken out and cultured.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347701 In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

1 Gene isolated from marrrow cells producing ADA is introduced into cells at embryonic stages.
2 Lymphocytes from patient's blood are grown in culture, outside the body.
3 Genetically engineered lumphocytes are not immortal cells.
4 Retroviral vector is introduced into these lymphocytes.
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347702 In order for gene therapy to be most effective, genes should be inserted in?

1 WBC
2 RBC
3 Stem cells
4 All the above
BIOXII12: BIOTECHNOLOGY AND ITS APPLICATIONS

347703 For the first time, gene therapy was tried on a 4 year old girl to treat which of the following enzyme deficiency in the year _?

1 Deoxyadenosine Aminase, 1983
2 Adenosine Deaminase, 1990
3 Adenosine Deaminase, 1983
4 Deoxyadenosine Aminase, 1990